AbstractBackgroundWhen the transplant candidates are receiving oral anticoagulation therapy before transplantation, it is crucial to have an urgent reversal strategy to prevent hemorrhagic complications perioperatively. The aim of this study was to present the experience with idarucizumab to reverse the anticoagulant activity of dabigatran prior to lung transplantation.MethodsA single‐center retrospective study was performed to analyze the clinical outcomes of idarucizumab use before lung transplantation.ResultsBetween July 2016 and June 2019, six patients were on dabigatran at the time of transplantation. Out of the six patients, four patients received idarucizumab. These four recipients received a median of 3 units (range 0‐4 units) of packed red blood cells (pRBCs) and 450 ml (range 250‐1500 ml) of intraoperative salvage of shed blood (cell saver blood) during the lung transplant. The two patients who were not administered idarucizumab received 5 units and 13 units of pRBCs and 900 ml and 3600 ml of cell saver blood, respectively. There was no grade 3 primary graft dysfunction (PGD) at 72 hours after transplantation or in‐hospital mortality in idarucizumab group. In the group without idarucizumab, there was one case of grade 3 PGD without any in‐hospital mortality.ConclusionDabigatran reversal with idarucizumab provides reasonable hemostasis during lung transplantation.